MAVENIR
20.2.2024 09:01:26 CET | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native solutions that run on any cloud, today announces a significant expansion of its OpenBeam™ radio portfolio with the launch of three new next-generation platforms that deliver advanced capabilities across diverse scenarios. This major enhancement of the OpenBeam solution set will further accelerate the deployment of 3GPP and O-RAN-compliant radios, with a focus on energy efficiency and engineered to support ULPI (Uplink Performance Improvement) functionality for Active Antenna Units (AAUs), in addition to the current O-RAN 7.2b specification.
Mavenir’s extended OpenBeam radio platform delivers an unparalleled breadth and depth of solutions that are AI-enabled and ‘green by design’, comprising:
- Wideband mMIMO AAUs: Mavenir’s next generation 64TRX massive MIMO AAU with up to 600MHz instantaneous bandwidth for Communication Service Providers (CSPs) with access to broad spectrum ranges. This halves the number of AAUs needed for deployment thereby streamlining network operations and reduces total cost of ownership.
- Wideband Multi-Band RRUs: Mavenir’s complete set of Remote Radio Units (RRUs) that support multiple bands with wideband power amplifiers – offering up to 480W output power and mid-band tri-band solution, in addition to the low-band tri-band solution already available as part of the OpenBeam portfolio. Wideband radio architecture allows operators to share power dynamically between bands, providing an overall improvement in energy efficiency.
- Next-Generation 32TRX mMIMO AAUs: Mavenir’s new generation of 32TRX Active Antenna Units (AAUs) powered by the Qualcomm® QRU100 5G RAN Platform to enhance performance, energy efficiency, and features for massive MIMO deployments.
In addition to the current O-RAN 7.2b specification, Mavenir’s AAU solutions are also engineered to support ULPI (Uplink Performance Improvement) allowing network operators to improve uplink performance, minimize latency, and reduce fronthaul bandwidth, especially in urban settings where network demand is high.
Mavenir's innovation and leadership in OpenBeam radio solutions have been recognized by global intelligence company ABI Research, which ranked Mavenir as the overall leader and top innovator in its recent Open RAN vendor comparison report (November 2023). The report praised Mavenir for addressing diverse industry needs with its broad portfolio of radio products spanning Micro, Macro, Millimetre Wave and mMIMO.
Job Benson, SVP, GM, Radio Business Unit at Mavenir said: “In live deployments across the world, our OpenBeam portfolio is demonstrating its value as a compelling enabler of growth for operators, providing radio solutions with the agility, cost-efficiency, and intelligence to meet critical network demands today, and a robust innovation platform as networks evolve and expand. Mavenir is pursuing an active programme of development to continuously enhance the features and capabilities of our standard-setting OpenBeam platforms, providing Communication Service Providers with the best-in-class solutions for their radio access network needs.”
Mavenir’s OpenBeam™ full radio portfolio will be displayed at the upcoming Mobile World Congress in Barcelona, Feb 26-29, in Hall 2 Stand 2H60. For more on Mavenir’s presence at the show visit www.mavenir.com/mwc-2024
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 300+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers.
For more information, please visit www.mavenir.com
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220628570/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom